Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Shanghai Pharmaceuticals Holding Co., Ltd is a leading healthcare company in China, primarily engaged in the distribution of pharmaceuticals and medical devices. With a robust network across 31 provinces and a diverse product portfolio, including over 40,000 SKUs, it leverages its scale and established relationships with healthcare providers to drive growth.
Shanghai Pharmaceuticals generates revenue primarily through the distribution of pharmaceuticals and medical devices to hospitals and pharmacies. Its competitive advantages include a vast distribution network, strong relationships with manufacturers, and a focus on high-demand therapeutic areas, allowing for pricing power and improved margins.
Changes in government healthcare policy impacting pharmaceutical pricing
Growth in China's healthcare spending driven by an aging population
Expansion of distribution network into underserved regions
Fluctuations in raw material costs affecting margins
Regulatory changes affecting drug pricing and reimbursement policies
Technological disruption in distribution channels, such as telemedicine
Intensifying competition from both domestic and international pharmaceutical distributors
Potential market entry of e-commerce platforms disrupting traditional distribution
Moderate debt levels (Debt/Equity of 0.81) could limit financial flexibility
Liquidity risks associated with inventory management and cash flow fluctuations
high - as a distributor of pharmaceuticals, the company's performance is closely tied to overall healthcare spending, which is influenced by GDP growth and consumer spending.
Moderate - rising interest rates can increase financing costs for expansion and capex, potentially impacting profitability and valuation multiples.
minimal - the company's operations are not heavily reliant on credit, although access to financing can impact growth initiatives.
value - the low Price/Sales (0.2x) and Price/Book (0.8x) ratios suggest potential for undervaluation.
moderate - historical volatility reflects the stability of the healthcare sector but can be influenced by regulatory changes.
